7,000,000 Shares LogicBio Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • October 5th, 2020 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
The undersigned is an executive officer or director of the Company or owner of shares of common stock, par value $0.0001 per share, of the Company (“Shares”) or of securities convertible into or exchangeable or exercisable for Shares. The Company proposes to conduct a public offering of Shares (the “Offering”) for which Jefferies LLC (“Jefferies”), Barclays Capital Inc. and William Blair & Company, L.L.C. will act as the representatives of the underwriters. The undersigned recognizes that the Offering will benefit each of the Company and the undersigned. The undersigned acknowledges that the underwriters are relying on the representations and agreements of the undersigned contained in this letter agreement in conducting the Offering and, at a subsequent date, in entering into an underwriting agreement (the “Underwriting Agreement”) and other underwriting arrangements with the Company with respect to the Offering.
INDEMNIFICATION AGREEMENTIndemnification Agreement • October 9th, 2018 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [ ], 2018, between LogicBio Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”).
OPEN MARKET SALE AGREEMENTSMLogicBio Therapeutics, Inc. • November 15th, 2019 • Biological products, (no disgnostic substances) • New York
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • July 2nd, 2019 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of July 2, 2019 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender and HORIZON TECHNOLOGY FINANCE CORPORATION, a Delaware corporation with an office located at 312 Farmington Avenue, Farmington, Connecticut 06032 (“Horizon”) (each a “Lender” and collectively, the “Lenders”), and LOGICBIO THERAPEUTICS, INC., a Delaware corporation with offices located at 99 Erie Street, Cambridge, Massachusetts 02139 (“Parent”) and LOGICBIO AUSTRALIA PTY LIMITED (ACN 625 479 610), an Australian proprietary limited company with offices located at 99 E
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 9th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is entered as of the last date set forth on the signature page below by and between LogicBio Therapeutics, Inc. (the “Company”) and [ ] (“Executive”).
LOGICBIO THERAPEUTICS, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 9th, 2018 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (this “Agreement”) is entered into as of the last date set forth on the signature page below (the “Effective Date”) by and between LogicBio Therapeutics, Inc. (the “Company”) and Tom Wilton (“Executive”).
LOGICBIO THERAPEUTICS, INC. NON-STATUTORY STOCK OPTION AGREEMENTNon-Statutory Stock Option Agreement • October 9th, 2018 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances)
This agreement (this “Agreement”) evidences a stock option granted by the Company to the individual named above (the “Participant”), pursuant to and subject to the terms of the LogicBio Therapeutics, Inc. 2018 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
AMENDMENT NO. 2 TO AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENTEquity) Agreement • August 13th, 2019 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS AMENDMENT NO. 2 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment”) is made as of June 3, 2019 (“Amendment Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 to Amended and Restated Exclusive (Equity) Agreement, dated as of May 3, 2018 (the “Original Agreement,” and as amended by this Amendment, the “Agreement”).
TENDER AND SUPPORT AGREEMENTTender and Support Agreement • October 3rd, 2022 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This TENDER AND SUPPORT AGREEMENT, dated as of October 3, 2022 (this “Agreement”), is between Alexion Pharmaceuticals, Inc., a Delaware corporation (“Parent”), Camelot Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and each of the undersigned stockholders of LogicBio Therapeutics, Inc., a Delaware corporation (the “Company”) set forth on Schedule I attached hereto (each a, “Stockholder” and together, the “Stockholders”).
PATENT & TECHNOLOGY LICENSE AGREEMENT AGT. NO. L2549-LogicBioTechnology License Agreement • October 9th, 2018 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Texas
This Patent and Technology License Agreement (“Agreement”) is between The Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas whose address is 201 West 7th Street, Austin, Texas 78701 on behalf of The University of Texas Southwestern Medical Center (“UT Southwestern”), a component institution of System, whose address is 5323 Harry Hines Boulevard, Dallas, Texas 75390-9094 (“Licensor”) and LogicBio Therapeutics, Inc., a Delaware corporation, with its principal place of business at 700 Main Street, Cambridge, MA 02139 (“Licensee”) (collectively, “Parties”, or singly, “Party”).
ContractLogicBio Therapeutics, Inc. • July 2nd, 2019 • Biological products, (no disgnostic substances) • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
LOGICBIO THERAPEUTICS, INC. CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT, RESTRICTED ACTIVITIES, AND ARBITRATION AGREEMENTEmployment Agreement • May 16th, 2022 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
As a condition of my employment with LogicBio Therapeutics, Inc. (“LogicBio”), its subsidiaries, affiliates, successors or assigns (together, the “Company”), and in consideration of my employment with the Company and my receipt of the compensation now and hereafter paid to me by Company, and in recognition of the fact that, as an employee of the Company, I will be granted access to the good will, trade secrets and other confidential information of the Company, and in exchange for other good and valuable consideration, including without limitation the stock option that will be granted to me, subject to the approval of the Company’s Board of Directors, under the Company’s 2018 Equity Incentive Plan on or after the date hereof, the sufficiency of which I hereby acknowledge, I agree to the following provisions of this LogicBio Therapeutics, Inc. Confidential Information, Invention Assignment, Restricted Activities, and Arbitration Agreement (this “Agreement”):
AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENTExclusive (Equity) Agreement • October 9th, 2018 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Amended and Restated Exclusive (Equity) Agreement (“Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and LogicBio Therapeutics, Inc. (“LogicBio”), a corporation having a principal place of business at 700 Main Street, Cambridge, MA 02139, is effective on the 31st day of January, 2018 (“Amendment Date”).
THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 10th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS THIRD AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of March 31, 2021 (the “Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender and HORIZON CREDIT II LLC, a Delaware limited liability company with an office located at 312 Farmington Avenue, Farmington, Connecticut 06032, as assignee of HORIZON TECHNOLOGY FINANCE CORPORATION, a Delaware corporation (“Horizon”) (each a “Lender” and collectively, the “Lenders”), and LOGICBIO THERAPEUTICS, INC., a Delaware corporation with offices located at 65 Hayden Ave 2nd Floor, Lexington MA 02421 (“Parent”) and LOGICBIO AUSTRALIA PTY LIMITED (ACN 625 479 61
AMENDMENT NO. 4 TO AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENTLogicBio Therapeutics, Inc. • August 10th, 2020 • Biological products, (no disgnostic substances) • California
THIS AMENDMENT NO. 4 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment No. 4”) is made as of April 29, 2020 (“Amendment No. 4 Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 dated as of May 3, 2018, and amended again by that certain Amendment No. 2 dated June 3, 2019, and amended again by that certain Amendment No. 3 dated January 29, 2020, to Amended and Restated Exclusive (Equity) Agreement (the “Original Agreement,” and as amended by this Amendment No. 4, the “Agreement”).
LOGICBIO THERAPEUTICS, INC.Incentive Plan Restricted Stock Agreement • October 9th, 2018 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Unless otherwise defined herein, the terms defined in the 2014 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Restricted Stock Agreement (the “Agreement”).
AMENDMENT NO. 6 TO AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENTOriginal Agreement • May 10th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS AMENDMENT NO. 6 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment No. 6”) is made as of March 29th, 2021 (“Amendment No. 6 Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 dated as of May 3, 2018, amended again by that certain Amendment No. 2 dated June 3, 2019, amended again by that certain Amendment No. 3 dated January 29, 2020, amended again by that certain Amendment No. 4 dated April 29, 2020, and amended again by that certain Amendment No. 5 dated October 30, 2020, to Amend
CONSULTANCY AGREEMENTConsultancy Agreement • August 9th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Consultancy Agreement (the “Agreement”) is entered into and effective June 1st 2021(the “Effective Date”) by and between Kyle Chiang (“Consultant”), an individual located at [**] and LogicBio Therapeutics, Inc. (“LogicBio”) with offices located at 65 Hayden Avenue, Floor 2, Lexington, MA 02421, USA. Consultant and LogicBio shall be referred to individually as a “Party” and together as the “Parties”.
CONSULTANCY AGREEMENTConsultancy Agreement • August 9th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Consultancy Agreement (the “Agreement”) is entered into and effective November 6th, 2020 (the “Effective Date”) by and between Bryan Yoon (“Consultant”), an individual located at [**] and LogicBio Therapeutics, Inc. (“LogicBio”) with offices located at 65 Hayden Avenue, Floor 2, Lexington, MA 02421, USA. Consultant and LogicBio shall be referred to individually as a “Party” and together as the “Parties”.
Exclusive Research Collaboration, License and Option Agreement Between LogicBio Therapeutics, Inc. and CANbridge Care Pharma Hong Kong LimitedExclusive Research Collaboration, License and Option Agreement • August 9th, 2021 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Exclusive Research Collaboration, License and Option Agreement (this “Agreement”) is entered into as of April 26, 2021 (the “Effective Date”) by and between CANbridge Care Pharma Hong Kong Limited, a Hong Kong limited liability company, having its registered address at FLAT/RM A 12/F, ZJ300, 300 Lockhart Road, Wan Chai, Hong Kong (“CANbridge”) and LogicBio Therapeutics, Inc., a Delaware corporation having its principal place of business at 65 Hayden Ave., Floor 2, Lexington, MA 02421, United States (“LogicBio”). CANbridge and LogicBio are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
PATENT LICENSE AGREEMENT NONEXCLUSIVE – SUBLICENSABLE This Agreement is based on the model Patent License Non-Exclusive Sublicensable Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of...Public Health Service • April 1st, 2019 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).
LOGICBIO THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 16th, 2022 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is entered as of the last date set forth on the signature page below (the “Effective Date”) by and between LogicBio Therapeutics, Inc. (the “Company”) and Daniel Gruskin (“Executive”).
LOGICBIO THERAPEUTICS, INC.Stock Option Agreement • October 9th, 2018 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Unless otherwise defined herein, the terms defined in the 2014 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”).
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • November 9th, 2020 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of September 28, 2020 (the “Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender and HORIZON CREDIT II LLC, a Delaware limited liability company with an office located at 312 Farmington Avenue, Farmington, Connecticut 06032, as assignee of HORIZON TECHNOLOGY FINANCE CORPORATION, a Delaware corporation (“Horizon”) (each a “Lender” and collectively, the “Lenders”), and LOGICBIO THERAPEUTICS, INC., a Delaware corporation with offices located at 99 Erie Street, Cambridge, Massachusetts 02139 (“Parent”) and LOGICBIO AUSTRALIA PTY LIMITED (ACN 625 479 610
AMENDMENT NO. 7 TOAgreement • March 4th, 2022 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
AGREEMENT (the “Amendment”) is made as of December 7, 2021 (“Amendment Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”) (together, the “Parties”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 dated as of May 3, 2018, amended again by that certain Amendment No. 2 dated June 3, 2019, amended again by that certain Amendment No. 3 dated January 29, 2020, amended again by that certain Amendment No. 4 dated April 29, 2020, amended again by that certain Amendment No. 5 dated October 30, 2020, and as amended again by that certain Amendment No. 6 dated March 2
LOGICBIO THERAPEUTICS, INC. CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT, RESTRICTED ACTIVITIES, AND ARBITRATION AGREEMENTLogicBio Therapeutics, Inc. • August 9th, 2021 • Biological products, (no disgnostic substances) • Massachusetts
As a condition of my employment with LogicBio Therapeutics, Inc. (“LogicBio”), its subsidiaries, affiliates, successors or assigns (together, the “Company”), and in consideration of my employment with the Company and my receipt of the compensation now and hereafter paid to me by Company, and in recognition of the fact that, as an employee of the Company, I will be granted access to the good will, trade secrets and other confidential information of the Company, and in exchange for other good and valuable consideration, including without limitation the stock option that will be granted to me, subject to the approval of the Company’s Board of Directors, under the Company’s 2018 Equity Incentive Plan on or after the date hereof, the sufficiency of which I hereby acknowledge, I agree to the following provisions of this LogicBio Therapeutics, Inc. Confidential Information, Invention Assignment, Restricted Activities, and Arbitration Agreement (this “Agreement”):
AT-WILL EMPLOYMENT, CONFIDENTIAL INFORMATION, INVENTION ASSIGNMENT, AND ARBITRATION AGREEMENTLogicBio Therapeutics, Inc. • August 9th, 2021 • Biological products, (no disgnostic substances) • California
As a condition of my employment with LogicBio Therapeutics, Inc., its subsidiaries, affiliates, successors or assigns (together, the "Company"), and in consideration of my employment with the Company and my receipt of the compensation now and hereafter paid to me by Company, I agree to the following provisions of this LogicBio Therapeutics, Inc. At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement (this “Agreement”):
AGREEMENT AND PLAN OF MERGER BY AND AMONG LOGICBIO THERAPEUTICS, INC. ALEXION PHARMACEUTICALS, INC. AND CAMELOT MERGER SUB, INC. Dated as of October 3, 2022Tender and Support Agreement • October 3rd, 2022 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This AGREEMENT AND PLAN OF MERGER, dated as of October 3, 2022 (this “Agreement”), is entered into by and among LogicBio Therapeutics, Inc., a Delaware corporation (the “Company”), Alexion Pharmaceuticals, Inc., a Delaware corporation (“Parent”), and Camelot Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub” and, collectively with the Company and Parent, the “Parties”).
CONSULTING AGREEMENTConsulting Agreement • September 23rd, 2022 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Consulting Agreement (the “Agreement”) is entered into and effective as of September 23, 2022 (the “Effective Date”) by and between Cecilia Jones (“Consultant”), located at [***], and LogicBio Therapeutics, Inc. (“LogicBio” or the “Company”), with its principal place of business at 65 Hayden Avenue, Floor 2, Lexington, MA 02421, USA. Consultant shall provide the Consulting Services (defined below) on behalf of Consultant under this Agreement. Consultant and LogicBio shall be referred to individually as a “Party” and together as the “Parties.”
LOGICBIO THERAPEUTICS, INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • October 9th, 2018 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances)
This agreement (this “Agreement”) evidences a stock option granted by the Company to the individual named above (the “Participant”), pursuant to and subject to the terms of the LogicBio Therapeutics, Inc. 2018 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
Amendment No. 2 to Patent & Technology License AgreementLicense Agreement • November 9th, 2020 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 to Patent & Technology License Agreement (“Amendment Two”) is made and entered into as of September 29, 2020 (the “Effective Date”) by and between LogicBio Therapeutics, Inc. a Delaware corporation, having a principal place of business at 65 Hayden Avenue, Floor 2, Lexington, MA 02421 (“LogicBio”) and The Board of Regents (“Board”) of The University of Texas System (“System”, an agency of the State of Texas whose address is 210 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas Southwestern Medical Center (“UT Southwestern”), a component institution of System, whose address is 5323 Harry Hines Boulevard, Dallas, Texas 75390-9094.
INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 25th, 2018 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 19th day of June, 2017, by and among LogicBio Therapeutics Inc., a Delaware corporation (the “Company”), each of the holders of Preferred Stock of the Company listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the holders of Common Stock of the Company listed on Schedule B hereto, each of whom is referred to herein as a “Common Holder” and any additional parties that become a party to this Agreement in accordance with Section 6.9 or Section 6.9 hereof.
LOGICBIO THERAPEUTICS, INC. CONSULTING AGREEMENTConsulting Agreement • August 13th, 2018 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Consulting Agreement (this “Agreement”) is made and entered into as of April 1, 2018 (the “Effective Date”) by and between LogicBio Therapeutics, Inc., a Delaware corporation with its principal place of business at c/o LabCentral, 700 North Main Street, Cambridge, MA 02139 (the “Company”), and Mark A. Kay, MD, PhD, an individual with his/her principal place of business at 1071 Peninsular CT ., Los Altos CA 94024 (“Consultant”) (each herein referred to individually as a “Party,” or collectively as the “Parties”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT LOGICBIO THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL AMENDMENT NO. 5 TO AMENDED AND RESTATED...LogicBio Therapeutics, Inc. • March 15th, 2021 • Biological products, (no disgnostic substances) • California
THIS AMENDMENT NO. 5 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment No. 5”) is made as of October 30, 2020 (“Amendment No. 5 Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 dated as of May 3, 2018, and amended again by that certain Amendment No. 2 dated June 3, 2019, amended again by that certain Amendment No. 3 dated January 29, 2020, and amended again by that certain Amendment No. 4 dated April 29, 2020, to Amended and Restated Exclusive (Equity) Agreement (the “Original Agreem
AMENDMENT NO. 3 TO AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENTEquity) Agreement • March 16th, 2020 • LogicBio Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS AMENDMENT NO. 3 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment No. 3”) is made as of January 29, 2020 (“Amendment No. 3 Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 dated as of May 3, 2018, and amended again by that certain Amendment No. 2, dated June 3, 2019, to Amended and Restated Exclusive (Equity) Agreement (the “Original Agreement,” and as amended by this Amendment No. 3, the “Agreement”).
